NCT02697630 - Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions

Metastatic Uveal Melanoma

Interventions

DRUG

Pembrolizumab

200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months

DRUG

Entinostat

5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months

Trial Locations (1)

Department of oncology, Sahlgrenska University Hospital, Gothenburg